Table 3.

Metabolic and immunosuppressive data before and after kidney transplantation in 97 uremic patients without known diabetes (DM) at baseline

ParameterTx GroupUremic Controls
Time 0Time 3 moTime 12 moTime 0Time 12 mo
Number of patients5757574040
Fasting p-glucose, mmol/L5.1 ± 0.55.6 ± 0.7a5.5 ± 0.7a5.05 ± 0.54.9 ± 0.9
p-glucose at 2 h, mmol/L7.4 ± 1.68.7 ± 3.17.8 ± 2.57.8 ± 1.77.8 ± 2.4
HbA1c, %5.2 ± 0.45.6 ± 0.5a5.6 ± 0.4a5.2 ± 0.45.3 ± 0.4
AUC insulin, pmol/L × 120 min35,358 ± 19,88436,977 ± 17,02345,970 ± 27,36729,606 ± 17,33025,745 ± 15,025
AUC glucose, mmol/L × 120 min948 ± 1571059 ± 287994 ± 237965 ± 191939 ± 244
ISI composite6.8 ± 3.94.9 ± 3.9b4.9 ± 2.8b7.9 ± 5.18.5 ± 4.9
Isecr36.9 ± 18.535.8 ± 17.345.8 ± 22c31.4 ± 17.328.4 ± 14.5
OGTT
    DM, n (%)011 (19)8 (14)c02 (5)
    IFG/IGT, n (%)0/19 (33)3/17 (35)1/16 (30)3/18 (50)2/14 (40)
    NGT, n (%)38 (67)26 (46)32 (56)20 (50)22 (55)
Estimated GRF, ml/min<1573.6 ± 20.3a78.0 ± 22.7a<15<15
BMI, kg/m224.4 ± 3.925.4 ± 3.926.3 ± 4.6c24.1 ± 3.024.0 ± 2.7
Waist-hip ratio0.92 ± 0.090.94 ± 0.090.93 ± 0.090.92 ± 0.080.91 ± 0.10
MAP, mmHg104 ± 1497 ± 1198 ± 15102 ± 16102 ± 14
AH2.5 ± 12 ± 12 ± 12 ± 12 ± 1
Beta-receptor blocker, n (%)27 (47)34 (71)35 (61)16 (39)20 (49)
Number of acute rejection episodes (%)08 (14)    9 (16)NANA
CMV disease, n (%)02 (4)5 (9)00
Prednisolone, n (%)12 (21)52 (91)52 (91)5 (2)5 (2)
Prednisolone, dose, mg613755
Tacrolimus, n (%)    1 (2)19 (33)21 (37)00
Tacrolimus, dose, mg022
Cyclosporine, n (%)    1 (2)36 (63)32 (56)00
Cyclosporine, dose, mg021414500
Azathioprine/sirolimus, n (%)02 (4)3 (5)00
MMF; Cellcept, n (%)    4 (7)52 (91)46 (81)00
MMF; Myfortic, n (%)02 (4)    7 (15)00
  • Values are given as mean ± SD unless otherwise noted. Wilcoxon rank sum test or unpaired t test was used where appropriate to test. NGT, normal glucose tolerance; AH, mean number of antihypertensive medications; CMV, cytomegalovirus; MMF, mycophenolate mofetil.

  • a Tx patients before versus after Tx P < 0.0005.

  • b Tx patients before versus after Tx P < 0.005.

  • c Tx patients before versus after Tx P < 0.05.